Anti-CD123 LV redirected T cells Therapy (Childrens Hospital of Philadelphia)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAnti-CD123 LV redirected T cells Therapy (Childrens Hospital of Philadelphia)
Drug Alias NameAutologous CD123-Directed CAR T-Cells Therapy (Childrens Hospital of Philadelphia)CART123
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsInterleukin-3 receptor subunit alpha modulators
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChildrens Hospital of Philadelphia
China Registration ClassN/A

Develop Information

Active CompaniesChildrens Hospital of Philadelphia
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A